BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:
Stifel 2024 Healthcare Conference in New York City
Monday, November 18, 2024, at 8:35 a.m. Eastern Time
Wolfe Research 2024 Healthcare Conference in New York City
Tuesday, November 19, 2024, at 4:10 p.m. Eastern Time
Nasdaq 51 st Investor Conference in London, UK
Tuesday, December 10, 2024, at 6:30 a.m. Eastern Time
Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at . Replays of the presentations will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the events and will be available for 90 days following the presentations.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit .
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
